Beijing Tiantan Biological Products (SHSE:600161) Piotroski F-Score: 4 (As of Jul. 16, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600161 Beijing Tiantan Biological Products Corp Ltd SHSE:600161
75 GF Score
Price ¥12.67
GF Value ¥23.94
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Beijing Tiantan Biological Products Piotroski F-Score?

Beijing Tiantan Biological Products SHSE:600161 -2.16% 75 Piotroski F-Score is 4 as of Jul. 16, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates SHSE:600161 with a GF Score™ of 75/100 and a GF Value™ of ¥23.94 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,333 Biotechnology companies, Beijing Tiantan Biological Products ranks better than 74.04% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Beijing Tiantan Biological Products has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Beijing Tiantan Biological Products's Piotroski F-Score or its related term are showing as below:

SHSE:600161' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Beijing Tiantan Biological Products was 8. The lowest was 3. And the median was 6.

Beijing Tiantan Biological Products  (SHSE:600161) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Beijing Tiantan Biological Products Piotroski F-Score Related Terms


Beijing Tiantan Biological Products Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Beijing Tiantan Biological Products's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tiantan Biological Products Piotroski F-Score Chart

Beijing Tiantan Biological Products Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 7.00 7.00 4.00

Beijing Tiantan Biological Products Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 3.00 4.00 4.00

SHSE:600161 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Beijing Tiantan Biological Products's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Tiantan Biological Products Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Beijing Tiantan Biological Products's Piotroski F-Score falls into.


SHSE:600161
75GF Score
Beijing Tiantan Biological Products Corp Ltd SHSE:600161
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 388.416 + 186.124 + 272.152 + 125.866 = ¥973 Mil.
Cash Flow from Operations was 99.735 + 318.8 + 221.852 + -15.508 = ¥625 Mil.
Revenue was 1792.627 + 1354.679 + 1702.964 + 1141.704 = ¥5,992 Mil.
Gross Profit was 807.647 + 544.154 + 748.516 + 394.928 = ¥2,495 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(16235.344 + 16521.817 + 16550.873 + 16583.016 + 16675.421) / 5 = ¥16513.2942 Mil.
Total Assets at the begining of this year (Mar25) was ¥16,235 Mil.
Long-Term Debt & Capital Lease Obligation was ¥71 Mil.
Total Current Assets was ¥8,353 Mil.
Total Current Liabilities was ¥947 Mil.
Net Income was 409.414 + 325.632 + 497.445 + 244.146 = ¥1,477 Mil.

Revenue was 1619.419 + 1231.987 + 1958.504 + 1317.766 = ¥6,128 Mil.
Gross Profit was 896.591 + 671.913 + 1045.688 + 604.487 = ¥3,219 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(14791.832 + 15139.378 + 15553.621 + 15869.522 + 16235.344) / 5 = ¥15517.9394 Mil.
Total Assets at the begining of last year (Mar24) was ¥14,792 Mil.
Long-Term Debt & Capital Lease Obligation was ¥79 Mil.
Total Current Assets was ¥8,054 Mil.
Total Current Liabilities was ¥1,121 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Beijing Tiantan Biological Products's current Net Income (TTM) was 973. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Beijing Tiantan Biological Products's current Cash Flow from Operations (TTM) was 625. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=972.558/16235.344
=0.05990375

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1476.637/14791.832
=0.09982786

Beijing Tiantan Biological Products's return on assets of this year was 0.05990375. Beijing Tiantan Biological Products's return on assets of last year was 0.09982786. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Beijing Tiantan Biological Products's current Net Income (TTM) was 973. Beijing Tiantan Biological Products's current Cash Flow from Operations (TTM) was 625. ==> 625 <= 973 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=70.94/16513.2942
=0.00429593

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=78.564/15517.9394
=0.00506279

Beijing Tiantan Biological Products's gearing of this year was 0.00429593. Beijing Tiantan Biological Products's gearing of last year was 0.00506279. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=8353.097/947.296
=8.81783202

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=8054.263/1120.502
=7.18808445

Beijing Tiantan Biological Products's current ratio of this year was 8.81783202. Beijing Tiantan Biological Products's current ratio of last year was 7.18808445. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Beijing Tiantan Biological Products's number of shares in issue this year was 2097.767. Beijing Tiantan Biological Products's number of shares in issue last year was 2034.547. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2495.245/5991.974
=0.41643121

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3218.679/6127.676
=0.52526912

Beijing Tiantan Biological Products's gross margin of this year was 0.41643121. Beijing Tiantan Biological Products's gross margin of last year was 0.52526912. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5991.974/16235.344
=0.36906973

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=6127.676/14791.832
=0.41426079

Beijing Tiantan Biological Products's asset turnover of this year was 0.36906973. Beijing Tiantan Biological Products's asset turnover of last year was 0.41426079. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+0+0+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Beijing Tiantan Biological Products has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Beijing Tiantan Biological Products (SHSE:600161) has a Piotroski F-Score of 4 as of Jul. 16, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Beijing Tiantan Biological Products and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Beijing Tiantan Biological Products' Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Beijing Tiantan Biological Products ranks #346 out of 1333 companies in the Biotechnology industry, placing it in the top 26%.
Is Beijing Tiantan Biological Products' Piotroski F-Score too high?
Beijing Tiantan Biological Products' current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Biotechnology industry median Piotroski F-Score is 3.00. Beijing Tiantan Biological Products' value of 4 is 33.3% above this industry median. Based on the distribution chart, Beijing Tiantan Biological Products ranks #346 out of 1333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beijing Tiantan Biological Products has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Tiantan Biological Products ranks #346 out of 1333 companies for Piotroski F-Score. This puts Beijing Tiantan Biological Products in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Beijing Tiantan Biological Products' value of 4 is 33.3% above this benchmark. Historically, Beijing Tiantan Biological Products' own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Beijing Tiantan Biological Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,333 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tiantan Biological Products's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Beijing Tiantan Biological Products and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tiantan Biological Products's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥23.94, compared to a current price of ¥12.67 — trading 47.1% below its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 33.3% above the Biotechnology industry median of 3.00. Beijing Tiantan Biological Products' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current Piotroski F-Score is 4 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued. The current stock price of ¥12.67 is trading 47.1% below its estimated GF Value™ of ¥23.94. GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.

Key valuation signals for SHSE:600161:

  • Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
  • GF Value™: ¥23.94 vs. price of ¥12.67 (47.1% below fair value)
  • GF Score™: 75/100 with 3 warning signs
  • Industry Position: 33.3% above the Biotechnology median (#346 of 1333)

No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beijing Tiantan Biological Products Business Description

Address No. 2, Shuangqiao Road, Chaoyang District, Beijing, CHN, 100024
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
75GF Score

Get the complete analysis for SHSE:600161

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.67
Price
¥23.94
GF Value